Latest Data For Edwards’ Sapien Suggest Steep Learning Curve For Doctors
This article was originally published in The Gray Sheet
Executive Summary
Analysts are disappointed with the mortality data in European registries of Edwards Lifesciences' Sapien transcatheter aortic heart valve, but are optimistic that outcomes will improve in the U.S. trial as physicians get better at implanting the device
You may also be interested in...
Heart Valve Market: PAVR Poised for Growth
Much like the early days of coronary stenting, percutaneous aortic valve replacement has captured the imagination of physicians and industry alike. Although many challenges remain, most physicians in the heart valve community appear optimistic that transcatheter aortic valve technologies will eventually achieve a prominent place in the treatment armamentarium, a development that would put these devices on track to achieve over $1 billion in sales within the next five years.
Vying Valves: Edwards’ Sapien Progresses, But CoreValve Remains A Threat
European data for Edwards Lifesciences' Sapien transcatheter heart valve are encouraging, but analysts have raised questions about design of the firm's planned U.S. trial of the device
Vying Valves: Edwards’ Sapien Progresses, But CoreValve Remains A Threat
European data for Edwards Lifesciences' Sapien transcatheter heart valve are encouraging, but analysts have raised questions about design of the firm's planned U.S. trial of the device
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: